This study analyzed tumor doubling times (TDT) in four cases of primary cutaneous melanoma with delayed diagnoses and their corresponding metastases. The median/mean TDT for primary melanomas was 94/144 days (range: 50–377 days), while metastatic melanomas exhibited a significantly faster TDT of 33/64 days (range: 8–212 days) (P = 0.01).
This 2019 retrospective study analyzed 1,458 patients with non-small cell lung cancer (NSCLC) who underwent curative resection between 1990 and 2006. Among them, 12 cases (0.8%) experienced ultra-late recurrence, defined as recurrence occurring more than 10 years post-surgery. The majority of these cases were adenocarcinomas, with two exhibiting anaplastic lymphoma
This 2015 population-based study analyzed data from 3,622 patients under 85 years who underwent curative resection for colon cancer between 1985 and 2000. The study found that between 5 and 10 years post-surgery, the cumulative recurrence rates were 2.9% for local recurrence and 4.3% for distant metastases. Notably, among men
This 2017 analysis of the Women’s Health Initiative (WHI) randomized trials examined the long-term effects of menopausal hormone therapy (HT) on mortality. Among 27,347 postmenopausal women followed for a median of 18 years, neither estrogen-alone nor estrogen-plus-progestin therapy was associated with increased all-cause or cause-specific mortality, including deaths from cardiovascular
This article presents a 16-year follow-up of the European Randomized Study of Screening for Prostate Cancer, which evaluates the long-term outcomes of prostate cancer screening using PSA testing. The study found that screening led to a modest reduction in prostate cancer mortality, but with a higher risk of overdiagnosis and
This 2015 commentary discusses a study involving 1,023 hypogonadal men undergoing testosterone therapy (TST) across three registries with a median follow-up of five years. The study found prostate cancer incidences of 2.3% and 1.5% in two cohorts, with no cases in the third. These rates are lower than those reported
A cohort study published in The Journal of Urology (2015) examined the incidence of prostate cancer in hypogonadal men receiving long-term testosterone therapy. Analyzing data from 1,023 patients, the study found no significant increase in prostate cancer risk, with 11 cases of prostate cancer diagnosed over the follow-up period. The
This randomized controlled trial followed 695 men with clinically localized prostate cancer over a median of 23.2 years, comparing radical prostatectomy to watchful waiting. The study found that radical prostatectomy significantly reduced prostate cancer-specific mortality (relative risk 0.55; 95% CI, 0.41–0.74; P7) and extracapsular extension significantly increased prostate cancer mortality
This matched-controlled study assessed the safety of estrogen replacement therapy (ERT) in breast cancer survivors by comparing 56 women who received ERT to matched controls based on age at diagnosis, stage of disease, and year of diagnosis. With a median follow-up of 12.8 years and a median ERT duration of
